Cargando…

Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes

Public health professionals and clinicians, in many countries, are immersed in the ongoing and upcoming vaccination programmes for COVID-19. Published information from vaccine trials is complex. There are important and helpful insights about the nature of the available and forthcoming vaccines, immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhopal, Sunil S., Olabi, Bayanne, Bhopal, Raj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society for Public Health. Published by Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846205/
https://www.ncbi.nlm.nih.gov/pubmed/33743214
http://dx.doi.org/10.1016/j.puhe.2021.01.011
_version_ 1783644692245643264
author Bhopal, Sunil S.
Olabi, Bayanne
Bhopal, Raj
author_facet Bhopal, Sunil S.
Olabi, Bayanne
Bhopal, Raj
author_sort Bhopal, Sunil S.
collection PubMed
description Public health professionals and clinicians, in many countries, are immersed in the ongoing and upcoming vaccination programmes for COVID-19. Published information from vaccine trials is complex. There are important and helpful insights about the nature of the available and forthcoming vaccines, immune responses and side-effects from phase II trials. We have systematically summarised information from 10 such trials on the nature of the vaccines, exclusions from the trials, immunological effects and side-effects. Some important information within these trial reports is not available in the phase III trial articles, so a complete picture requires examination of phase II and phase III trials for each vaccine. We recommend our systematic approach for the examination of other upcoming COVID-19 vaccine phase II and III trials.
format Online
Article
Text
id pubmed-7846205
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Royal Society for Public Health. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-78462052021-02-01 Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes Bhopal, Sunil S. Olabi, Bayanne Bhopal, Raj Public Health Short Communication Public health professionals and clinicians, in many countries, are immersed in the ongoing and upcoming vaccination programmes for COVID-19. Published information from vaccine trials is complex. There are important and helpful insights about the nature of the available and forthcoming vaccines, immune responses and side-effects from phase II trials. We have systematically summarised information from 10 such trials on the nature of the vaccines, exclusions from the trials, immunological effects and side-effects. Some important information within these trial reports is not available in the phase III trial articles, so a complete picture requires examination of phase II and phase III trials for each vaccine. We recommend our systematic approach for the examination of other upcoming COVID-19 vaccine phase II and III trials. The Royal Society for Public Health. Published by Elsevier Ltd. 2021-04 2021-01-29 /pmc/articles/PMC7846205/ /pubmed/33743214 http://dx.doi.org/10.1016/j.puhe.2021.01.011 Text en © 2021 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Bhopal, Sunil S.
Olabi, Bayanne
Bhopal, Raj
Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes
title Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes
title_full Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes
title_fullStr Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes
title_full_unstemmed Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes
title_short Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes
title_sort vaccines for covid-19: learning from ten phase ii trials to inform clinical and public health vaccination programmes
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846205/
https://www.ncbi.nlm.nih.gov/pubmed/33743214
http://dx.doi.org/10.1016/j.puhe.2021.01.011
work_keys_str_mv AT bhopalsunils vaccinesforcovid19learningfromtenphaseiitrialstoinformclinicalandpublichealthvaccinationprogrammes
AT olabibayanne vaccinesforcovid19learningfromtenphaseiitrialstoinformclinicalandpublichealthvaccinationprogrammes
AT bhopalraj vaccinesforcovid19learningfromtenphaseiitrialstoinformclinicalandpublichealthvaccinationprogrammes